AMGN exits its August 4 earnings print into a wave of upward analyst revisions, with the stock up nearly 3% on the day and a consensus that — for the first time in weeks — has started to catch up to where the shares are trading.
The analyst response to Q2 was almost uniformly constructive. Six firms raised price targets on August 5 alone. Oppenheimer, Scotiabank, and BMO Capital all moved to $450, while RBC lifted to $400 and Wells Fargo nudged to the same level. The mean target has risen to $371.93 — still below the current $390.02 close, which means the stock remains above consensus even after today's revisions. The one notable holdout is Truist Securities, which raised to $362 while keeping a Hold, and Morgan Stanley had trimmed its target to $333 just weeks ago. The Street is broadly positive but split: bulls point to Repatha, Tezspire, and Uplizna momentum; bears flag limited upside at current valuation and pipeline risk from Phase 3 data on Dazodalibep and Tezspire's EoE indication, both expected in H2 2026.
Positioning tells a quiet story after the event risk clears. Short interest has eased slightly to 2.39% of free float — a low reading that has been drifting around the 2.3–2.4% range since the mid-July peak near 2.7%. The lending market remains completely unconstrained: availability is running at roughly 4,785% of shares short, meaning there are nearly 48 times more shares available to borrow than are currently short. Cost to borrow has nudged up 13% on the week to 0.55%, a modest tick rather than any sign of stress. The ORTEX short score has eased to 36.7, continuing its retreat from the 38.2 high registered on July 22. There is no short-squeeze dynamic here, and nothing in the borrow market suggests one is building.
Options have drifted toward slightly elevated caution. The put/call ratio closed at 0.865 — above its 20-day average of 0.813 and running at a z-score of 1.6, the highest reading in several weeks. That is not an extreme reading by any measure; the 52-week high on the PCR is 1.11. But the directional move is worth noting: the PCR was consistently below 0.80 through most of July and has been climbing since late July, suggesting options traders are incrementally more interested in downside protection even as the stock gained.
Valuation multiples have re-rated modestly higher over the past month. The trailing P/E has expanded to 16.8x, up roughly 0.44 turns over 30 days, and price-to-book has risen to 17.5x, adding 0.6 turns in the same window. EV/EBITDA is holding near 11.8x. None of these moves are dramatic, but they confirm the stock has been re-rating upward into earnings — which is part of why the stock now trades above even the freshly-raised consensus target. The dividend factor score ranks in the 88th percentile, reflecting Amgen's consistent payout profile, though the dividend history data in this snapshot is stale and should not be quoted directly.
Among close peers, the week has been mixed. REGN is the standout, up 9.4% on the week, well ahead of Amgen's flat-to-slightly-down performance on the week (down 0.8% despite today's jump). INCY and ABBV both fell around 7% over the same period, while BIIB and GILD were roughly flat. The next scheduled catalyst for AMGN is the Q3 report, currently expected around November 5 — the intervening period means attention will shift to whether the H2 2026 pipeline readouts on Dazodalibep and the Tezspire EoE programme arrive on schedule and with clean data.
See the live data behind this article on ORTEX.
Open AMGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
